Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer.

MLA

Lee, Kangkook, et al. “Repeat Biopsy Procedures and T790M Rates after Afatinib, Gefitinib, or Erlotinib Therapy in Patients with Lung Cancer.” Lung Cancer (Amsterdam, Netherlands), vol. 130, Apr. 2019, pp. 87–92. EBSCOhost, https://doi.org/10.1016/j.lungcan.2019.01.012.

APA

Lee, K., Kim, Y., Jung, H. A., Lee, S.-H., Ahn, J. S., Ahn, M.-J., Park, K., Choi, Y.-L., & Sun, J.-M. (2019). Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer. Lung Cancer (Amsterdam, Netherlands), 130, 87–92. https://doi.org/10.1016/j.lungcan.2019.01.012

Chicago

Lee, Kangkook, Youjin Kim, Hyun Ae Jung, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Yoon-La Choi, and Jong-Mu Sun. 2019. “Repeat Biopsy Procedures and T790M Rates after Afatinib, Gefitinib, or Erlotinib Therapy in Patients with Lung Cancer.” Lung Cancer (Amsterdam, Netherlands) 130 (April): 87–92. doi:10.1016/j.lungcan.2019.01.012.